Articles from Inquis Medical

Inquis Medical, the leading innovator in the treatment of venous thromboembolic disease, today announced the launch of SENSE-PE, an all-comer post-market registry evaluating the safety and efficacy of the AVENTUS™ Thrombectomy System in patients treated for acute pulmonary embolism (PE). Cleared by the FDA for the treatment of PE in June 2025, AVENTUS is the only thrombectomy platform combining integrated tissue-sensing technology and directional aspiration with autologous blood reinfusion to address unmet clinical needs and enhance procedural efficiency.

Pioneering device combines precision clot removal with autologous blood reinfusion to address unmet needs in PE treatment

MENLO PARK, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational Device Exemption (IDE) trial evaluating the safety and efficacy of the company’s Aventus Thrombectomy System for the treatment of pulmonary embolism (PE).

Results of AVENTUS IDE Trial presented at SCAI Scientific Sessions

Inquis Medical, a pioneering medical technology company specializing in advanced thrombectomy systems, today announced the successful closure of its $40 million Series B financing round. This oversubscribed round was led by Marshall Wace, a globally recognized investment firm, with strong participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. The funding positions Inquis Medical for significant growth and development as it advances its cutting-edge technologies and prepares for commercialization.

Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology